Searchable abstracts of presentations at key conferences in endocrinology

ea0025p234 | Pituitary | SFEBES2011

The risk of cardiac valvulopathy in cabergoline-treated endocrine patients in a district general hospital

Balaguruswamy Saravanan , Lewis Natalie , McNulty Sid , Furlong Niall

Aim: Over the last decade, cardiac valvular fibrosis has been associated with the use of high dose (ergot-derived) dopamine agonist therapy in Parkinson’s disease. Although the risk in endocrine patients appears significantly lower, routine echocardiographic monitoring is now recommended. This study evaluated the incidence of significant cardiac valvulopathy in endocrine patients treated with cabergoline in a District General Hospital Population, and compliance with MHRA ...